Gordon B. Mills

Gordon B. Mills
Institutions
Alma mater University of Alberta, Edmonton
Known for discovery of PI3K

Gordon B. Mills is the Weiss Distinguished University Chair in Cancer Medicine, chair of the department of systems biology, co Director of the Ovarian Cancer Moon Shot, Co-Director Sheikh Khalifa bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and Director of the Kleberg Center for Molecular Markers at MD Anderson Cancer Center.

He is most well known for his discoveries in the PI3K pathway in breast cancer.[1]

Mills received his BS in 1975, MD in 1977, and PhD in 1984, all from the University of Alberta, Edmonton.[2] He did a postdoc in immunology at the Hospital for Sick Children in Toronto and then joined the faculty at the University of Toronto in 1985 as an assistant professor and director of oncology research. He was recruited to MD Anderson in 1994.[1]

Along with his research in PI3K, he focuses on signaling pathways and markers for targeted therapy.[3] He and Lewis C. Cantley lead the Targeting PI3K in Women’s Cancers Stand Up To Cancer initiative.

His research has been funded by many sources such as the National Institutes of Health, National Cancer Institute, U.S. Department of Defense, AstraZeneca, Adelson Medical Research Foundation, Breast Cancer Research Foundation, GlaxoSmithKline, American Association for Cancer Research, and the Susan G. Komen Breast Cancer Foundation.[2][4]

Awards

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.